ACASTI PHARMA INC (ACST) Stock Price, Forecast & Analysis
USA - NASDAQ:ACST - CA00430K8656 - Common Stock
ACST Key Statistics, Chart & Performance
The current stock price of ACST is 3.37 USD. In the past month the price increased by 8.01%. In the past year, price increased by 40.42%.
ACST Latest News, Press Relases and Analysis
ACST Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.96 | 935.69B | ||
| JNJ | JOHNSON & JOHNSON | 18.67 | 466.81B | ||
| MRK | MERCK & CO. INC. | 10.32 | 227.17B | ||
| PFE | PFIZER INC | 7.97 | 145.04B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.43 | 99.17B | ||
| ZTS | ZOETIS INC | 18.95 | 53.23B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.48 | 22.72B | ||
| VTRS | VIATRIS INC | 4.81 | 13.06B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.81 | 11.36B | ||
| CORT | CORCEPT THERAPEUTICS INC | 89.78 | 8.33B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.63 | 4.09B |
Related stock screener links
About ACST
Company Profile
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The company is headquartered in Laval, Quebec. The company went IPO on 2013-03-07. The firm is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.
Company Info
ACASTI PHARMA INC
3009, Boul. De La Concorde East, Suite 102
Laval QUEBEC H7E 2B5 CA
CEO: Jan D'Alvise
Employees: 32
Phone: 14506864555
ACASTI PHARMA INC / ACST FAQ
What does ACST do?
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The company is headquartered in Laval, Quebec. The company went IPO on 2013-03-07. The firm is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.
What is the stock price of ACASTI PHARMA INC today?
The current stock price of ACST is 3.37 USD. The price decreased by -0.88% in the last trading session.
What is the dividend status of ACASTI PHARMA INC?
ACST does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACST stock?
ACST has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of ACST stock?
ACASTI PHARMA INC (ACST) operates in the Health Care sector and the Pharmaceuticals industry.
Should I buy ACST stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ACST.
ACST Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ACST. When comparing the yearly performance of all stocks, ACST is one of the better performing stocks in the market, outperforming 86.9% of all stocks.
ACST Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACST. ACST has a great financial health rating, but its profitability evaluates not so good.
ACST Financial Highlights
Over the last trailing twelve months ACST reported a non-GAAP Earnings per Share(EPS) of -1.04. The EPS increased by 78.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.41% | ||
| ROE | -19.28% | ||
| Debt/Equity | 0 |
ACST Forecast & Estimates
7 analysts have analysed ACST and the average price target is 8.16 USD. This implies a price increase of 142.14% is expected in the next year compared to the current price of 3.37.